Drug Trial Radar · NCT00927797
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
Last checked: Nov 19, 2026Latest source record: Jun 25, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
185
Planned (sponsor's estimate)
Start
Feb 2005
Primary completion
Jan 2009
Study completion Jan 2012
Sponsor
- Lead sponsor
- Heidelberg UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Diakonie Krankenhaus Schwäbisch Hall, Germany; Klinikum der Universitaet Muenchen, Grosshadern; Klinikum am Plattenwald, Bad Friedrichshall, Germany; Diakonie-Klinikum Stuttgart; Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany; Universitätsmedizin Mannheim
- First posted
- Jun 25, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The combination of Fludarabine and Cyclophosphamide have yielded overall response rates of over 80% in previously untreated patients with indolent Non-Hodgkin-Lymphoma. However, hematotoxicity rates were high with Grade 3 and 4 toxicities of over 50%. Several studies have indicated that the treatment with Pentostatin and Cyclophosphamide causes lower hematotoxicity rates than the combination of Fludarabine and Cyclophosphamide. To evaluate the efficacy and safety of treatment with Pentostatin/Cyclophosphamide immuno-chemotherapy for patients with newly diagnosed or relapsed Immunocytoma/Morbus Waldenström, B-cell chronic lymphocytic leukemia (B-CLL) and other indolent CD20-positive B-NHL, an open, non-randomized, multi-center prospective phase II-study to evaluate the efficacy and safety of treatment with immuno-chemotherapy is conducted. Treatment consists of 6 courses of Pentostatin (4mg/m² on day 1), Cyclophosphamide (600mg/m² on day 1) and Rituximab (375mg/m² on day 0) administered every three weeks. Patients achieving complete or partial remission undergo maintenance therapy consisting of 8 courses of Rituximab (375mg/m²) administered every three months over a period of 2 years.
Conditions
- Immunocytoma/Morbus Waldenström
- B-Cell Non-Hodgkin's Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
Interventions
Cyclophosphamide, Pentostatin, RituximabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: overall response rateTime frame: after 6 months and after 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.